Back

Quizartinib promotes cardiac inflammation that contributes to cardiotoxicity

20 June 2026 (10:45 - 11:45)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology insights into immunity and immune checkpoint inhibitors Research and New Technology CCO Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Yasmin Alshoubaki

University Hospital Basel, Basel (Switzerland)

8 More presentations in this session

Presentation thumbnail
VISTA, a next-generation immune checkpoint: expression in heart failure and cardiovascular safety of inhibition
Doctor M. Jakab (Budapest, HU)
Abstract Slides
Presentation thumbnail
Troponin and NTproPNB levels before starting cancer therapy with immune checkpoint inhibitors can predict all-cause mortality
Professor S. Szmit (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Angiotensin II unmasks immune checkpoint inhibitor-induced arrhythmias and conduction defects in mice
Doctor A. Ramalingam (Budapest, HU)
Abstract Slides
Presentation thumbnail
Immune checkpoint inhibitor-induced alterations in thymic gene expression and spatial distribution
Doctor A. Kulin (Budapest, HU)
Abstract Slides
Presentation thumbnail
Immune checkpoint inhibitors induce immune-mediated myocarditis and inflammasome activation in a tumor-bearing mouse model
Mr S. Lledo (Marseille, FR)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology insights into immunity and immune checkpoint inhibitors

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 10:45 CET
You may be interested in
thumbnail
Congress Presentation
Unveiling doxorubicin-induced cardiotoxicity: into the heart with single-cell resolution
20 June 2025
thumbnail
Congress Presentation
Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study
3 September 2019
thumbnail
Congress Presentation
Arthritis induced systemic inflammation aggravates murine heart failure
1 September 2025
thumbnail
Congress Presentation
Cardiotoxicity in ibrutinib-treated patients: incidence, management, and impact on treatment outcomes
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources